top of page
Helping patients understand KRAS cancer research.
KRAS Cancer News & Updates
Expanded Access Programs for Cancer Patients: Navigating the Complex Process
Expanded Access Can Feel Slow When Treatment Is Urgent. Each EAP has its own criteria for who may receive the drug. If the EAP is for pancreatic cancer, that does not mean it is available for other cancers unless those cancer types are specifically included in the EAP criteria.
Every day counts, why does it take so long?
Cancer Treatment & Clinical Trial Eligibility: What Patients Need to Know
Once you know your options, the next question is: Am I eligible? Here’s how doctors typically determine if a patient qualifies for a clinical trial or specific therapy—regardless of cancer type.
6 things that matter...
Terri Conneran KRAS Kickers
Jul 11, 2025
What Every Cancer Patient Should Know About Today’s Treatment Options
..just been diagnosed—or are navigating next step—you’re not alone. Cancer care has changed dramatically in the last decade. Today, you may have more treatment choices than ever before. This post is designed to help you understand your options and feel confident asking the right questions.
Terri Conneran KRAS Kickers
Jul 11, 2025
What Is ASCO Conference—And Should Cancer Patients Care?
💡 Why It Matters to Patients:
Even if you’re not in the room, what happens at ASCO can shape your treatment options—now and in the future. KRAS-driven cancers (lung, colon, pancreatic, and rare cancers) are a major area of focus at ASCO. knowing what’s coming can help you:
-Ask better questions -
-Stay ahead of the curve -
-Find hope in options you didn’t know existed- Gen-Me Medicine—where cancer care is about matching the right treatment to your unique molecular fingerpri
Terri Conneran KRAS Kickers
Jun 10, 2025
Rare Pancreas cancer FGFR + KRAS trial - comes to you
Rare Pancreatic cancer trial comes to you! FGFR + KRAS
Terri Conneran KRAS Kickers
May 19, 2025
Getting ahold of KRAS Science: Visiting Kevan Shokat at his UCSF Lab
By the time I met Kevan Shokat, KRAS G12D was already the name of the devil my body was fighting.
Then Kevan did something extraordinary. He made me a three dimensional model of KRAS, had it painted, and sent it to me with a handwritten letter.
How KRAS Became Druggable: Kevan Shokat and the Pocket That Opened a New Era of RAS Drugs
more than 60 additional drugs targeting the RAS family are now in development. What began with a chemical foothold in KRAS G12C has become an expanding field of RAS drug discovery. Why This Matters for People With KRAS Cancer The science also explains why knowing the exact KRAS variant matters.
Where can patients find the NCCN guidelines used to guide cancer treatment?
NCCN Guidelines help clinicians determine what evaluations are appropriate, which treatment options are supported by current evidence, when additional testing may be important, and how care may change as a cancer changes.For patients, NCCN offers a version for patients.
bottom of page